SLC12A5 and epilepsy: Given the established role of dysregulated expression of two cation–chloride cotransporter proteins, NKCC1 and KCC2, in susceptibility to convulsion generation and epilepsy development, the present study evaluates the anticonvulsant potential of bumetanide (BUM, 10 mg/kg, i.p.)and probenecid (PROB, 50 mg/kg, i.p.), the potential of adenosine receptor activation (NECA, 1 mg/kg, i.p.)to modify the anticonvulsant efficacy of BUM, and the changes in NKCC1 and KCC2 protein expression levels in carbamazepine (CBZ)-resistant animals.